Business Overview: SunHydrogen, Inc. (OTCQB: HYSR)

---

Executive Summary

SunHydrogen, Inc. (formerly HyperSolar) is a pre-revenue research and development company based in Santa Barbara, California, developing technology to produce renewable hydrogen directly from sunlight and water — without a separate electrolyzer or external electrical bias. Founded with roots going back to 2009, the company's goal is a low-cost, direct-to-hydrogen alternative to today's standard "solar panel + electrolyzer" approach.

SunHydrogen matters not because of current commercial scale — it has essentially no revenue — but because it represents a speculative, early-stage bet on a genuinely different approach to green hydrogen production at a time when hydrogen is widely discussed as a decarbonization tool for heavy industry and transport. It is best understood as a technology-development company, not an operating business, and should be sized and risk-weighted accordingly.

---

1. Core Business Model & How They Work

SunHydrogen has no product sales; its "business model" today is converting R&D milestones and investor capital into technology that it hopes to eventually license or commercialize:

[ Capital Raised (equity/ATM offerings) ] ➡️ [ Nanoparticle / Thin-Film PEC R&D ] ➡️ [ Patent Filings ] ➡️ [ Pilot-Scale Demonstration Systems ] ➡️ [ Future Licensing or Manufacturing Partnership (not yet achieved) ]

Key Operational Drivers

1. Two Parallel Technology Tracks: (a) nanoparticle-based photoelectrosynthetically active heterostructures, and (b) thin-film solar cell-based hydrogen modules — both aimed at splitting water into hydrogen and oxygen using only sunlight, with no external power source or standalone electrolyzer stack.
2. Photoelectrochemical (PEC) Core Technology: Light absorbed by a semiconductor generates voltage and charge carriers that drive the water-splitting reaction directly at catalyst surfaces, which the company argues removes the cost and complexity of conventional electrolyzer and power-conditioning equipment.
3. Patent-First Strategy: With no near-term product revenue, intellectual property is effectively the company's only durable asset; it holds patents including a photoelectrochemical reactor for hydrogen production and a multi-junction artificial photosynthetic cell design.
4. Dilutive Financing Dependency: The company funds its R&D entirely through equity issuance (including equity purchase agreements such as its prior arrangement with GHS Investments), meaning continued operations depend on its ability to keep raising capital from investors, not on product revenue.
5. No Current Reportable Segments: SunHydrogen operates as a single R&D segment; there is no product-line or geographic segmentation to report.

---

2. Product Portfolio (Technology in Development — Pre-Commercial)

There is no revenue-generating product today — every line above is a pre-commercial R&D program.

---

3. Competitive Landscape

SunHydrogen sits inside the much larger and well-capitalized "green hydrogen" industry, but its specific direct-solar-to-hydrogen approach has few direct technological peers:

• Nel ASA (Norway) and other established electrolyzer manufacturers represent the dominant, commercially proven approach to green hydrogen (solar/wind electricity feeding a standalone electrolyzer) — this is the incumbent technology SunHydrogen is trying to leapfrog, and Nel and peers have vastly greater capital, manufacturing scale, and commercial deployments already in the field.
• Bloom Energy and Heliogen compete in the broader clean-energy/hydrogen-adjacent space with fundamentally different technologies (fuel cells and concentrated solar, respectively) — not direct PEC rivals, but competitors for investor and partner attention and capital within the same thematic space.
• Ascent Solar Technologies and other thin-film photovoltaic developers overlap with SunHydrogen's thin-film hydrogen-module track from the materials-science side.
• SunHydrogen's genuinely direct PEC-approach peers (such as academic spinouts and smaller private research ventures) are mostly pre-commercial as well — this is a nascent technology race with no clear commercial winner yet, including SunHydrogen itself.

---

4. Strategic Strengths & Risks

Potential Strengths

• Patent estate specific to direct solar-to-hydrogen conversion, a technical approach that, if it works at scale, could meaningfully undercut the capital cost of conventional electrolyzer-based green hydrogen.
• Relatively well-capitalized for a pre-revenue microcap, with roughly $37 million of working capital as of its most recent fiscal year-end (June 30, 2025), giving it more runway than many comparably speculative R&D names.

Strategic Risks & Vulnerabilities

1. Zero Revenue, Entirely Pre-Commercial: The company has recorded no revenue in its most recent two fiscal years; there is no proof yet that its core technology can be manufactured and deployed at commercially viable cost or scale.
2. Total Dependence on Capital Markets: With an accumulated deficit exceeding $100 million and ongoing cash burn (FY2025 net loss of ~$8.2 million), SunHydrogen's ability to continue its R&D program hinges entirely on continued, likely dilutive, equity financing — its prior equity purchase facility with GHS Investments has expired, leaving no committed forward funding source disclosed.
3. Technology and Execution Risk: Pursuing two parallel, unproven technology tracks (nanoparticle and thin-film PEC) rather than one validated path increases the risk that capital and management attention are spread too thin to reach commercial pilot scale on either.
4. Competing Against an Incumbent, Capital-Intensive Industry: Even if SunHydrogen's PEC approach works technically, it must still out-compete an electrolyzer industry (Nel and peers) that already has manufacturing scale, utility and industrial customer relationships, and government policy support that SunHydrogen has not yet secured.

---

5. Financial Overview

---

6. Summary Conclusion

SunHydrogen is not, in any conventional sense, an operating business with customers, revenue, or a defensible market position yet — it is a patent-protected R&D bet that direct solar-to-hydrogen water splitting can eventually undercut the cost of conventional electrolyzer-based green hydrogen production. The company's relatively healthy ~$37 million working-capital position buys it time that many pre-revenue microcaps don't have, but the central risk remains binary and unresolved: either the nanoparticle or thin-film PEC technology reaches commercially viable pilot scale before capital runs out and investor patience fades, or it does not, and the accumulated patent estate becomes the company's only remaining asset of value.